---
title: "YZYBIO's biosimilar Y225 clinical trial application approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270915083.md"
description: "YZYBIO-B announced that the clinical trial application for the biosimilar drug Y225 has been approved by the National Medical Products Administration of China. Y225 is a bispecific antibody biosimilar used for the treatment of Hemophilia A, specifically the drug Shuyou Lile (Aimeisai Zhu Dan Zhi Ye, anti-FIX and FX)"
datetime: "2025-12-28T10:39:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270915083.md)
  - [en](https://longbridge.com/en/news/270915083.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270915083.md)
---

# YZYBIO's biosimilar Y225 clinical trial application approved

YZYBIO-B (02496.HK) announced that the clinical trial application for the biosimilar Y225 has been approved by the National Medical Products Administration of China. Y225 is a bispecific antibody used for the treatment of Hemophilia A, a biosimilar to Shuyou Lile (Aimeisai Zhu Dan Kua, anti-FIX and FX) injection

### Related Stocks

- [02496.HK](https://longbridge.com/en/quote/02496.HK.md)

## Related News & Research

- [Changzhou Investment-backed Tianchen Biomed lists in Hong Kong, raises HKD 1.36 billion](https://longbridge.com/en/news/290381537.md)
- [Shandong Boan Biotech shareholders adopt restricted share unit incentive scheme at AGM](https://longbridge.com/en/news/290440061.md)
- [Zai Lab grants directors 178,968 restricted shares under 2024 equity incentive plan](https://longbridge.com/en/news/290431681.md)
- [CSPC Pharmaceutical Expands On-Market Purchases for 2026 Share Award Scheme](https://longbridge.com/en/news/290431089.md)
- [Paradigm Shift: Tracing the Migration from Consumer Aggregation to AI Infrastructure](https://longbridge.com/en/news/290323447.md)